Real‐world <scp>KINDLE‐Latin</scp> America subset data on treatment patterns and clinical outcomes in patients with stage <scp>III</scp> non‐small‐cell lung cancer

Martín, Claudio; Puello-Guerrero, Adrián; Mas-Lopez, Luis Alberto; Campos-Gómez, Saúl; Orlando-Orlandi, Francisco J; Gallegos, Luis Fernando Tejado; Huggenberger, Reto

doi:10.1002/cam4.4990

Cited by 4 publications

(1 citation statement)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2,3 Despite these barriers, lung cancer researchers in Latin America have published findings highlighting regionspecific trends in lung cancer epidemiology, differential resource utilization, and survival responses to lung cancer treatments, thus highlighting the need for increased efforts in lung cancer research in this region. [4][5][6][7][8] Of particular interest, Latin American cancer specialists have advocated for increased participation in lung cancer clinical trials as a vehicle for driving forward regional cancer research. [9][10][11] To begin addressing these barriers in cancer research, multinational oncology cooperative groups (OCGs) such as the Latin American Consortium for the Investigation of Lung Cancer (CLICaP, organized in 2011) and the Latin American Cooperative Oncology Group (LACOG, organized in 2009) were founded.…”

Section: Introductionmentioning

confidence: 99%

Lung Cancer Clinical Trials in Latin America in the Era of Cooperative Groups: A 20-Year Analysis

Knapp,

Nygaard,

Cassinat

et al. 2024

JCO Glob Oncol

View full text Add to dashboard Cite

PURPOSE The aim of this study is to characterize lung cancer treatment clinical trials in Latin America before (January 2001-December 2011) and after (January 2012-December 2021) the organization of major Latin American oncology cooperative groups. MATERIALS AND METHODS Interventional clinical trials were identified in ClinicalTrials.gov using the search terms “lung cancer,” country filters for 20 Latin American countries, and study start dates January 1, 2001-December 31, 2011, and January 1, 2012-December 31, 2021. Clinical trials were categorized as either originating in Latin America (LA) or outside Latin America (non-LA) with participation of Latin American countries. Descriptive statistics, two-sided Z-scores, and chi-square analyses with 95% CIs were calculated. RESULTS Overall, 273 clinical trials involving Latin American countries between 2001 and 2021 were identified. Comparing 2001-2011 with 2012-2021, there was an increase in total clinical trials (100 v 173; P < .001). Only 9% (26 of 273) of all trials were LA trials. There was a marked decrease in the proportion of LA trials (14% v 7%, P = .058) and estimated enrollment to LA trials (3,245 v 1,190 patients; P < .001). Recruiting of patients with EGFR (29% v 7%; P < .01) and KRAS (18% v 2%; P < .01) driver mutations also decreased. Trial participation was highest in Brazil, Mexico, Argentina, Chile, and Peru and increased over time: Brazil (61 v 108; 77% increase), Mexico (40 v 88; 120% increase), Argentina (50 v 78; 56% increase), Chile (25 v 57; 128% increase), and Peru (14 v 37; 164% increase). CONCLUSION There was a significant increase in clinical trial participation by Latin American countries, from 2001-2011 to 2012-2021. However, there were few clinical trials which originated in Latin America or focused on patients with driver mutations.

show abstract

Section: Introductionmentioning

confidence: 99%

Lung Cancer Clinical Trials in Latin America in the Era of Cooperative Groups: A 20-Year Analysis

Knapp,

Nygaard,

Cassinat

et al. 2024

JCO Glob Oncol

View full text Add to dashboard Cite

show abstract

Real‐world KINDLE‐Latin America subset data on treatment patterns and clinical outcomes in patients with stage III non‐small‐cell lung cancer

et al. 2022

View full text Add to dashboard Cite

Introduction Stage III non‐small‐cell lung cancer (NSCLC) management is challenging given the heterogeneous nature of the disease. The LATAM subset of the real‐world, global KINDLE study reported the treatment patterns and clinical outcomes for LATAM from the pre‐immuno‐oncology era. Methods The study was conducted in seven countries (Argentina, Chile, Colombia, Dominican Republic, Mexico, Peru and Uruguay) in stage III NSCLC (American Joint Committee on Cancer, 7th edition) diagnosed between January 2013 and December 2017. Retrospective data from patients' medical records (index date to the end of follow‐up) were collected. Summary statistics, Kaplan–Meier survival estimates and a two‐sided 95% confidence interval (CI) were provided. Cox proportional hazard model was used for univariate and multi‐variate analyses. Results A total of 231 patients was enrolled, the median age was 65.0 years (range 21.0–89.0), 60.6% were males, 76.6% had smoking history, 64.0% had adenocarcinoma and 28.7% underwent curative resection. Multiple treatment regimens (>25) were used; chemotherapy alone was the most common (24.8%). The overall median progression‐free survival (mPFS) and median overall survival (mOS) were 14.8 months (95% CI, 12.1–18.6) and 48.6 months (95% CI, 34.7 to not calculable). Significantly better mPFS and mOS were observed for stage IIIA with curative surgery and resectable tumours and stage IIIB with an Eastern Cooperative Oncology Group score of 0/1, female gender, resectable tumours, adenocarcinoma and curative surgery (p < 0.05). Conclusion Results show diversity in treatment practices and the corresponding clinical outcomes in stage III NSCLC. There is a need to streamline treatment selection and sequencing to decrease relapse rates after initial therapy.

show abstract

Estimation of the Clinical, Economic, and Social Burden of Stage IV Non-Small Cell Lung Cancer in Mexico

Añorve Bailon,

Picó-Guzmán,

Cifuentes

et al. 2024

PharmacoEconomics Open

View full text Add to dashboard Cite

Introduction Lung cancer continues to be the leading cause of death among cancer patients worldwide. This study aimed to estimate the clinical, economic, and social burdens of stage IV non-small cell lung cancer (NSCLC) in private and public healthcare centers in Mexico, utilizing real-world evidence. Methods The study population included patients >18 years of age diagnosed with stage IV NSCLC who received cancer treatment at the Centro Médico Nacional Siglo XXI (IMSS), the Centro Médico Nacional “20 de Noviembre” (ISSSTE), the Mexican Institute of Respiratory Diseases (INER), and the Medical Center ABC (American British Cowdray) from 1 January 2019 to 31 December 2020. The analysis included evaluation of epidemiological data, treatment regimens, and clinical outcomes, and emphasized pharmacological and non-pharmacological treatments, including detailed follow-up investigations, as part of comprehensive clinical management. Additionally, the study assessed the social burden through variables such as working-age absenteeism and presenteeism and caregiver productivity loss, as well as economic burden, considering both clinical and social components, with costs adjusted to 2022 Mexican pesos (MXN) values. Results A total of 188 patients with metastatic NSCLC were studied. The main type of NSCLC tumor found in the sample was adenocarcinoma (81%). Treatment regimens included pharmacological treatments (78%), non-pharmacological treatments (25%), and palliative care (24%). Complications were present in 73% of the cohort, while 60% presented adverse events. Clinical management costs of up to MXN1,001,579 per patient in the public sector and MXN2,140,604 in the private sector were reported. It was estimated that working-age patients lose 84–335 days yearly due to absenteeism and presenteeism, while caregivers report a productivity loss equivalent to 13–30 days due to the management of NSCLC patients. These indirect costs of NSCLC contribute to the social burden. A working-age patient with stage IV disease is associated with an average indirect cost of MXN49,731–178,287 in public institutions, while in private institutions, the cost elevates to MXN438,103. Conclusions This study highlights the substantial clinical, economic, and social burdens of stage IV NSCLC in Mexico, revealing significant disparities between public and private healthcare sectors. It underscores the urgent need for standardized practices and equitable care across all systems.

show abstract

Real‐world KINDLE‐Latin America subset data on treatment patterns and clinical outcomes in patients with stage III non‐small‐cell lung cancer

Cited by 4 publications

References 34 publications

Lung Cancer Clinical Trials in Latin America in the Era of Cooperative Groups: A 20-Year Analysis

Lung Cancer Clinical Trials in Latin America in the Era of Cooperative Groups: A 20-Year Analysis

Real‐world KINDLE‐Latin America subset data on treatment patterns and clinical outcomes in patients with stage III non‐small‐cell lung cancer

Estimation of the Clinical, Economic, and Social Burden of Stage IV Non-Small Cell Lung Cancer in Mexico

Contact Info

Product

Resources

About